Rituximab (RTX) Therapy in Patients With Active TAO
OphthalmopathyThyroid-AssociatedThyroid Associated Ophthalmopathy is condition affecting the eyes of about 10% of patients with Graves disease. Its combination of protrusion affecting the looks of the patient and pain is often severely affecting the quality of life among these patients. The standard treatment for this illness today is intravenous glucocorticoids together with methotrexate. The purpose of this study is to evaluate the effect of rituximab on patients that do not respond to or relapse after conventional therapy.
Safety Study of Tivanisiran to Treat Dry Eye
Dry Eye DiseaseThis study will examine the safety of tivanisiran sodium eye drops versus vehicle when dosed once daily for 1 year in subjects with signs and symptoms of dry eye disease (DED).
Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry...
Dry Eye SyndromeThe study objective is to assess the efficacy and safety of cenegermin (rhNGF) ophthalmic solution at 20 mcg/mL concentration administered three times daily for 4 weeks in patients with severe Sjogren's dry eye disease (DED) who are under chronic treatment with topical Cyclosporine A (CsA).
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]...
Retinitis PigmentosaRetinitis6 moreThe purpose of the study is to evaluate the safety and efficacy of a single intravitreal injection of virally-carried Multi-Characteristic Opsin (MCO-010).
Efficacy of Repeated Low-Level Red-Light Therapy in Myopia Control
MyopiaRefractive Errors1 moreThe purpose of this study is to determine if repeated low-level red-light therapy can slow myopia progression in Chinese schoolchildren.
A Study of TL-925 as a Treatment for Dry Eye Disease
Dry Eye DiseaseIn this prospective, Phase 2, multicenter, randomized, double-masked, placebo-controlled, parallel-arm study, approximately 100 subjects with moderate to severe dry eye disease (DED) will be randomly assigned (1:1) to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally BID. The study will comprise two phases: 2-weeks screening/run-in and 4-weeks double-masked treatment.
The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease
Dry Eye DiseaseThe objective of this study is to compare the safety and efficacy of OK-101 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.
Single Ascending Dose Study in Participants With LCA10
Leber Congenital Amaurosis 10Inherited Retinal Dystrophies6 moreThe purpose of this study is to evaluate the safety, tolerability and efficacy of a single escalating doses of EDIT-101 administered via subretinal injection in participants with LCA10 caused by a homozygous or compound heterozygous mutation involving c.2991+1655A>G in intron 26 of the CEP290 gene ("LCA10-IVS26").
A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512
Dry Eye DiseaseThis will be a 12-month, multicenter, vehicle-controlled, double-masked, randomized Phase 3 study conducted at approximately 10 sites in the United States. All subjects enrolled will have dry eye disease (DED). The study will consist of a Baseline (Day 1) visit as well as visits at Day 14, Day 90, Day 180, Day 270, and Day 365 (Study Exit).
Prospective, Randomized, Masked, Controlled Trial To Evaluate The Safety And Effectiveness Of The...
Dry EyeMeibomian Gland DysfunctionTo demonstrate the safety and effectiveness of TearCare® procedures compared to Restasis® to treat the signs and symptoms of dry eye disease in adult patients.